A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes

Inclusion Criteria: * Have type 2 diabetes * Are on stable treatment for type 2 diabetes for at least 90 days prior to screening * Have a BMI ≥ 27 kg/m2 * Have a stable body weight (\<5% body weight change) for 90 days prior to screening Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)…